Felicia Roncolato

659 total citations
31 papers, 247 citations indexed

About

Felicia Roncolato is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Felicia Roncolato has authored 31 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Reproductive Medicine and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Felicia Roncolato's work include Ovarian cancer diagnosis and treatment (12 papers), Prostate Cancer Treatment and Research (7 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Felicia Roncolato is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Prostate Cancer Treatment and Research (7 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Felicia Roncolato collaborates with scholars based in Australia, Canada and United States. Felicia Roncolato's co-authors include Linda Mileshkin, Melina L Willson, Kristina Lindemann, Julie Martyn, Martin R. Stockler, Michael Friedländer, Madeleine King, Felix Hilpert, Eriko Aotani and Éric Pujade-Lauraine and has published in prestigious journals such as Journal of Clinical Oncology, Cochrane Database of Systematic Reviews and Annals of Oncology.

In The Last Decade

Felicia Roncolato

29 papers receiving 247 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Felicia Roncolato Australia	8	133	75	59	55	43	31	247
Mary M. Mullen United States	11	136 1.0×	66 0.9×	72 1.2×	22 0.4×	58 1.3×	29	274
C. Tyler Kirkland United States	4	108 0.8×	51 0.7×	85 1.4×	53 1.0×	22 0.5×	6	292
J Crétin France	8	94 0.7×	70 0.9×	32 0.5×	72 1.3×	40 0.9×	31	257
Lihui Han China	12	115 0.9×	52 0.7×	130 2.2×	56 1.0×	114 2.7×	19	390
Sarah Bétrian France	9	59 0.4×	55 0.7×	29 0.5×	26 0.5×	53 1.2×	25	173
Gilles Freyer France	8	167 1.3×	23 0.3×	35 0.6×	39 0.7×	24 0.6×	21	248
Annie Lukanova Sweden	6	82 0.6×	25 0.3×	66 1.1×	46 0.8×	15 0.3×	6	220
Nicolas Delanoy France	8	90 0.7×	35 0.5×	18 0.3×	101 1.8×	27 0.6×	32	208
Ratna Paul Finland	9	50 0.4×	24 0.3×	34 0.6×	58 1.1×	46 1.1×	26	330
Sanya Anand United States	4	232 1.7×	52 0.7×	60 1.0×	106 1.9×	35 0.8×	5	365

Countries citing papers authored by Felicia Roncolato

Since Specialization

Citations

This map shows the geographic impact of Felicia Roncolato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felicia Roncolato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felicia Roncolato more than expected).

Fields of papers citing papers by Felicia Roncolato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felicia Roncolato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felicia Roncolato. The network helps show where Felicia Roncolato may publish in the future.

Co-authorship network of co-authors of Felicia Roncolato

This figure shows the co-authorship network connecting the top 25 collaborators of Felicia Roncolato. A scholar is included among the top collaborators of Felicia Roncolato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felicia Roncolato. Felicia Roncolato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roncolato, Felicia, Madeleine King, Rachel O’Connell, et al.. (2024). Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Gynecologic Oncology. 185. 128–137. 3 indexed citations

Niazi, Tamim, Paul L. Nguyen, Scott Williams, et al.. (2024). Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).. Journal of Clinical Oncology. 42(4_suppl). 328–328. 2 indexed citations

Subramaniam, Shalini, Diana Adams, Annette Tognela, et al.. (2024). Patients' perception of the benefits of palliative systemic therapy for advanced cancer. Internal Medicine Journal. 54(5). 735–741.

Liang, Roger J., Diana Adams, Felicia Roncolato, et al.. (2024). Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors. Clinical Genitourinary Cancer. 22(4). 102116–102116. 1 indexed citations

Campbell, Rachel, Madeleine King, Martin R. Stockler, et al.. (2023). Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice. Patient Related Outcome Measures. Volume 14. 111–126. 3 indexed citations

Kichenadasse, Ganessan, Carole A. Harris, Howard Gurney, et al.. (2022). Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4537–4537. 4 indexed citations

McBride, Sean M., Tamim Niazi, Scott Williams, et al.. (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology. 40(6_suppl). TPS284–TPS284. 1 indexed citations

Niazi, Tamim, Sean M. McBride, Scott Williams, et al.. (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology. 40(16_suppl). TPS5103–TPS5103. 2 indexed citations

Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2021). UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.. Journal of Clinical Oncology. 39(6_suppl). 325–325. 2 indexed citations

10.

Niazi, Tamim, Scott Williams, Ian D. Davis, et al.. (2020). DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). TPS385–TPS385. 2 indexed citations

11.

Roncolato, Felicia, Rachel O’Connell, Florence Joly, et al.. (2019). Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS). Gynecologic Oncology. 156(1). 45–53. 6 indexed citations

12.

Tran, Ben, Hosein Kouros‐Mehr, Lisa G. Horvath, et al.. (2019). A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 30. v353–v353.

13.

Roncolato, Felicia, Emma Gibbs, Chee Khoon Lee, et al.. (2017). Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Annals of Oncology. 28(8). 1849–1855. 26 indexed citations

14.

Roncolato, Felicia, Dominique Berton-Rigaud, Rachel O’Connell, et al.. (2017). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology. 148(1). 36–41. 30 indexed citations

15.

Roncolato, Felicia, Florence Joly, Rachel O’Connell, et al.. (2017). Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology. 35(15_suppl). 5575–5575. 1 indexed citations

16.

Roncolato, Felicia, Florence Joly, Rachel O’Connell, et al.. (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study. The Oncologist. 22(9). 1117–1124. 18 indexed citations

17.

Roncolato, Felicia, Johnathan Man, John Simes, et al.. (2017). Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis. JCO Precision Oncology. 1(1). 1–12. 2 indexed citations

18.

He, Emily, Nicholas J. Hawkins, Gabriel Mak, et al.. (2016). The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. The Oncologist. 21(5). 618–625. 12 indexed citations

19.

Roncolato, Felicia, Rachel O’Connell, Luke Buizen, et al.. (2016). Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology. 34(15_suppl). 5508–5508. 2 indexed citations

20.

Williams, Scott, Ian D. Davis, Christopher J. Sweeney, et al.. (2015). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).. Journal of Clinical Oncology. 33(15_suppl). TPS5078–TPS5078. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact